LZAGY News and Press, Lonza Group AG ADR From 02/11/24

2024-02-11 12:00:03 ET More on Eli Lilly, Novo Nordisk, etc. Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript ...

2024-01-27 10:40:00 ET Summary Lonza Group aims to increase revenue by double digits by 2028 through aggressive expansion in the CDMO space. Lonza expects to increase its EBITDA margin to 32%-34% by 2028 and maintain a low debt ratio. The company plans to generate 25% of its r...

2024-01-26 13:14:05 ET Lonza Group AG (LZAGY) Q4 2023 Earnings Conference Call January 26, 2024, 08:00 AM ET Company Participants Albert Baehny - CEO ad Interim and Chairman of the Board of Directors Philippe Deecke - CFO Conference Call Participants Rich...

2024-01-26 11:52:39 ET More on Lonza Lonza not planning to manufacture GLP-1 drugs: report Historical earnings data for Lonza Group Dividend scorecard for Lonza Group Financial information for Lonza Group Seeking Alpha’s Quant Rating on Lonza G...

2024-01-26 09:43:23 ET More on Lonza Group AG Lonza not planning to manufacture GLP-1 drugs: report Seeking Alpha’s Quant Rating on Lonza Group AG Historical earnings data for Lonza Group AG Dividend scorecard for Lonza Group AG Financial infor...

2024-01-25 10:23:28 ET Major earnings expected before the bell on Friday include: American Express ( AXP ) Booz Allen Hamilton Holding ( BAH ) Colgate-Palmolive ( CL ) Norfolk Southern ( NSC ) Oxford Lane Capital ( OXLC ) Read the full artic...

FFW Corp. (FFWC) is expected to report for Q2 2024 ResMed Inc. (RMD) is expected to report $1.81 for Q2 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2023-12-31 ChoiceOne Financial Services Inc. (COFS) is expected to report $0.64 for Q4 2023 First ...

Lonza Group AG ADR (LZAGY) is expected to report for Q4 2023

2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...

2023-11-17 16:16:14 ET More on Lonza Group AG Lonza: The Day Has Come, And We Lower Our Expectation Lonza Group: Downside Scenario Already Priced In Historical earnings data for Lonza Group AG Dividend scorecard for Lonza Group AG Financial informatio...